Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid.
about
Global Emergence and Dissemination of Enterococci as Nosocomial Pathogens: Attack of the Clones?Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society.Newer antibiotics for the treatment of peritoneal dialysis-related peritonitis.New Gram-Positive Agents: the Next Generation of Oxazolidinones and Lipoglycopeptides.Multidrug-resistant organisms in liver transplant: Mitigating risk and managing infections.Critical role of tedizolid in the treatment of acute bacterial skin and skin structure infectionsSuccessful Treatment of Prosthetic Joint Infection due to Vancomycin-resistant Enterococci with Tedizolid.In vitro activity of tedizolid against Staphylococcus aureus and Streptococcus pneumoniae collected in 2013 and 2014 from sites in Latin American countries, Australia, New Zealand, and China.Tedizolid susceptibility in linezolid- and vancomycin-resistant Enterococcus faecium isolates.Activities of Tedizolid and Linezolid Determined by the Reference Broth Microdilution Method against 3,032 Gram-Positive Bacterial Isolates Collected in Asia-Pacific, Eastern Europe, and Latin American Countries in 2014.In vitro activity of linezolid alone and combined with other antibiotics against clinical enterococcal isolates.
P2860
Q26745991-963DE4A0-3582-4E5F-AFD3-BCBAE0C8CF9AQ36078359-DB372B5A-099A-4E0B-9493-20679E8CF472Q37119083-67E4CC69-EC3B-4A3E-BB26-6F820771E0BCQ38768071-3C7917E0-876C-4A4C-BD02-E0924ED74200Q38845084-2F4F4E1F-ABDF-450B-B20F-8BE485AEB277Q39067666-8A12C73E-FFE3-4E23-B28D-8E0D945113E8Q40243103-80D7FABC-7136-47C6-BEBC-5ADF9F0E8E58Q40525718-64B80DA2-267E-4D6B-A3B6-3C4BDAB96102Q40575502-70CA86E5-01B3-4F76-97B6-DCFFFE186925Q40633323-ECD0E963-CCB3-4785-B916-E4CA03EA1D1FQ41996646-A0E144B5-A41F-47DF-A8B3-2228304025AE
P2860
Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Evaluation of tedizolid agains ...... ycin, daptomycin or linezolid.
@en
type
label
Evaluation of tedizolid agains ...... ycin, daptomycin or linezolid.
@en
prefLabel
Evaluation of tedizolid agains ...... ycin, daptomycin or linezolid.
@en
P2860
P356
P1476
Evaluation of tedizolid agains ...... mycin, daptomycin or linezolid
@en
P2093
Animesh Raut
Michael J Rybak
P2860
P304
P356
10.1093/JAC/DKV302
P407
P577
2015-10-16T00:00:00Z